A 6-year-old child with osteogenesis imperfecta—a genetic bone disease caused by a COL1A1 mutation—also developed ambiguous genitalia and hormone imbalances, marking the first documented case combining these two conditions in a 46,XY child. The discovery suggests genetic mutations affecting bone development may simultaneously impact reproductive system function, highlighting the need for comprehensive medical evaluation in rare genetic disorders.
Doctors discovered something extremely rare: a 6-year-old child with osteogenesis imperfecta (a genetic condition causing weak bones) also had ambiguous genitalia, meaning their reproductive organs didn’t develop in the typical way for either males or females. According to Gram Research analysis, this is the first reported case combining these two conditions in a 46,XY child. The child had a mutation in the COL1A1 gene, which normally helps build strong bones. Blood tests showed hormone imbalances that may have affected reproductive development. The case highlights how genetic mutations can affect multiple body systems at once and why children with rare conditions need care from many different medical specialists.
Key Statistics
A 2026 case report documented the first known coexistence of osteogenesis imperfecta due to COL1A1 mutation with ambiguous genitalia in a 46,XY child, showing that genetic mutations can affect multiple body systems simultaneously.
The child in this case report showed elevated follicle-stimulating hormone at 16.03 mIU/mL, low luteinizing hormone at 1.35 mIU/mL, and markedly reduced testosterone, indicating significant hormone imbalances alongside the bone disease.
This single case report represents the first documented instance of osteogenesis imperfecta with the specific p.Ile40Thr COL1A1 mutation occurring together with reproductive development disorders in a 46,XY individual.
The Quick Take
- What they studied: A single child with both weak bones (osteogenesis imperfecta) and ambiguous genitalia to understand how these two rare conditions could occur together
- Who participated: One 6-year-old child with a genetic mutation in the COL1A1 gene, experiencing repeated bone fractures, blue-tinted eyes, short height, and reproductive development differences
- Key finding: This is the first documented case of osteogenesis imperfecta caused by COL1A1 mutation occurring alongside ambiguous genitalia in a 46,XY child, suggesting the genetic mutation may affect both bone and reproductive development
- What it means for you: If you or a family member has osteogenesis imperfecta, doctors should check hormone levels and reproductive development, as genetic mutations can affect multiple body systems. This case shows why comprehensive medical evaluation is essential for rare genetic conditions.
The Research Details
This is a case report, which means doctors documented the medical history and findings from one specific patient. The 6-year-old child came to medical attention because of repeated bone fractures from minor injuries, blue-tinted whites of the eyes, and shorter-than-normal height—all signs of osteogenesis imperfecta. During examination, doctors also noticed the child had ambiguous genitalia, meaning reproductive organs that didn’t match typical male or female development patterns.
The medical team performed multiple tests to understand what was happening. They checked the child’s chromosomes (the genetic material that determines sex) and found 46,XY, which typically indicates male development. However, blood tests showed unusual hormone levels: high follicle-stimulating hormone (FSH at 16.03 mIU/mL), low luteinizing hormone (LH at 1.35 mIU/mL), and very low testosterone. These hormone imbalances suggested the reproductive system wasn’t developing normally.
Genetic testing revealed a mutation in the COL1A1 gene (specifically p.Ile40Thr), which is responsible for making type I collagen—the protein that gives bones their strength. This same mutation explained the weak bones, but doctors wondered if it might also be affecting reproductive development.
Case reports are important because they document unusual or never-before-seen combinations of medical conditions. When doctors encounter something completely new, they publish it so other physicians worldwide know to look for similar patterns. This case matters because it shows that genetic mutations can affect multiple body systems simultaneously—not just bones, but also reproductive development. Understanding these connections helps doctors provide better care for patients with rare genetic conditions.
As a case report of a single patient, this study cannot prove cause-and-effect relationships or apply findings to other people. However, the diagnosis was confirmed through genetic testing, which is the gold standard for identifying mutations. The medical team used multiple specialists (endocrinologists, geneticists, and others) to evaluate the child comprehensively. The main limitation is that this describes just one child, so we cannot know how common this combination is or whether other children with similar mutations would have the same reproductive issues.
What the Results Show
The child presented with classic signs of osteogenesis imperfecta: bones that broke easily from minor falls or injuries, blue-tinted whites of the eyes (called blue sclerae), and shorter height than expected for age. Genetic testing confirmed a mutation in the COL1A1 gene, which produces the protein that makes bones strong and flexible.
The unexpected finding was the presence of ambiguous genitalia—reproductive organs that didn’t develop in the typical pattern for males or females. Despite having 46,XY chromosomes (the genetic marker for male development), the child’s hormone levels were abnormal. Follicle-stimulating hormone was elevated at 16.03 mIU/mL (normal range is much lower), while luteinizing hormone was very low at 1.35 mIU/mL, and testosterone was markedly reduced.
These hormone imbalances suggested the child’s reproductive system wasn’t functioning properly. The doctors hypothesized that the same COL1A1 mutation affecting bone development might also be interfering with the development or function of the reproductive glands (gonads). The child also showed signs of possible partial adrenal insufficiency, meaning the adrenal glands weren’t producing enough hormones.
Beyond the primary findings, the case documented that the child’s condition required treatment with zoledronate (a medication that strengthens bones), calcium supplements, and vitamin D—standard care for osteogenesis imperfecta. The child needed ongoing follow-up from multiple medical specialists including orthopedic surgeons (bone doctors), endocrinologists (hormone specialists), and geneticists. This multidisciplinary approach was essential because the child had overlapping conditions affecting different body systems.
According to Gram Research analysis, this is the first reported case in medical literature combining osteogenesis imperfecta caused by COL1A1 mutation with ambiguous genitalia in a 46,XY child. While osteogenesis imperfecta is well-documented and reproductive development disorders are recognized separately, the coexistence of both conditions in one patient had never been reported before. This suggests either that the combination is extremely rare, or that it hasn’t been recognized and documented previously.
This is a single case report, so the findings apply only to this one child. We cannot determine whether other children with the same COL1A1 mutation would experience reproductive development issues. The case doesn’t prove that the mutation caused the reproductive problems—it only shows they occurred together. Long-term follow-up information is limited, so we don’t know how the child’s condition will progress over time. Additionally, the exact mechanism by which the COL1A1 mutation might affect reproductive development remains unclear and requires further research.
The Bottom Line
Children diagnosed with osteogenesis imperfecta should receive comprehensive medical evaluation including hormone testing and assessment of reproductive development, as genetic mutations can affect multiple body systems. Treatment should include bone-strengthening medications (like zoledronate), calcium and vitamin D supplementation, and regular monitoring by multiple specialists. Any child with ambiguous genitalia should undergo thorough genetic testing to identify underlying mutations. These recommendations are based on this single case and clinical experience with rare genetic conditions.
Parents and relatives of children with osteogenesis imperfecta should be aware that genetic mutations can have effects beyond bone health. Healthcare providers caring for children with rare genetic conditions should consider comprehensive evaluation of multiple body systems. Geneticists and endocrinologists should be alert to unusual combinations of symptoms that might indicate overlapping genetic effects. This case is less relevant to the general population but important for families affected by osteogenesis imperfecta.
Bone-strengthening treatments typically show effects over months to years, with reduced fracture rates becoming apparent within 6-12 months of starting medication. Reproductive development monitoring requires ongoing assessment over years, as puberty and sexual maturation occur gradually during childhood and adolescence. Long-term multidisciplinary follow-up is essential for managing both skeletal and reproductive aspects of this condition.
Frequently Asked Questions
Can osteogenesis imperfecta affect reproductive development?
This case report documents the first known instance of osteogenesis imperfecta occurring with ambiguous genitalia in a 46,XY child, suggesting the COL1A1 genetic mutation may affect reproductive development. However, this is a single case, so the frequency of this combination remains unknown.
What hormone levels indicate reproductive problems in children with bone disorders?
In this case, elevated follicle-stimulating hormone (16.03 mIU/mL), low luteinizing hormone (1.35 mIU/mL), and markedly reduced testosterone suggested reproductive system dysfunction. Children with genetic bone disorders should have hormone testing if reproductive development appears abnormal.
How is osteogenesis imperfecta with reproductive issues treated?
This child received annual zoledronate infusions to strengthen bones, plus calcium and vitamin D supplementation. Treatment required ongoing care from multiple specialists including orthopedic surgeons, endocrinologists, and geneticists to address both skeletal and reproductive health.
Why is genetic testing important for children with ambiguous genitalia?
Genetic testing can identify mutations affecting multiple body systems. This case shows that a COL1A1 mutation caused both weak bones and reproductive development issues, demonstrating why comprehensive genetic evaluation is essential for understanding overlapping conditions.
What should parents do if their child has osteogenesis imperfecta?
Ensure comprehensive medical evaluation including hormone testing and reproductive development assessment, as genetic mutations can affect multiple systems. Work with a multidisciplinary team of specialists and maintain consistent treatment with bone-strengthening medications and supplements.
Want to Apply This Research?
- Track bone health metrics including number of fractures, pain levels, and medication adherence (zoledronate infusions, calcium, vitamin D). Users can log each fracture event, pain intensity on a 1-10 scale, and mark completed doses of supplements and treatments.
- Set reminders for daily calcium and vitamin D supplementation, schedule quarterly zoledronate infusions, and maintain a fracture log to identify patterns or triggers. Users can also track physical activity modifications recommended by their orthopedic team to prevent injuries.
- Establish a long-term tracking system that monitors fracture frequency trends over 6-12 month periods, medication compliance, and communication with the multidisciplinary care team. Create alerts for scheduled endocrine follow-ups and hormone testing to ensure comprehensive monitoring of both skeletal and reproductive health.
This case report describes a single patient and cannot be applied to predict outcomes in other individuals. Osteogenesis imperfecta and disorders of reproductive development are serious medical conditions requiring evaluation and care from qualified healthcare professionals. If you or your child has symptoms of osteogenesis imperfecta (frequent fractures, blue-tinted eyes, short stature) or concerns about reproductive development, consult with a pediatrician, geneticist, and endocrinologist for proper diagnosis and treatment. This article is for educational purposes and should not replace professional medical advice, diagnosis, or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.